These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 37548904)
1. Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics. Bloomfield-Clagett B; Rahman M; Smith K; Concato J Clin Pharmacol Ther; 2023 Nov; 114(5):1002-1005. PubMed ID: 37548904 [TBL] [Abstract][Full Text] [Related]
2. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases. Vaghela S; Tanni KA; Banerjee G; Sikirica V Orphanet J Rare Dis; 2024 Mar; 19(1):117. PubMed ID: 38475874 [TBL] [Abstract][Full Text] [Related]
3. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. Purpura CA; Garry EM; Honig N; Case A; Rassen JA Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771 [TBL] [Abstract][Full Text] [Related]
4. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making. Yuan L; Rahman M; Concato J Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484 [TBL] [Abstract][Full Text] [Related]
5. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020. Arondekar B; Duh MS; Bhak RH; DerSarkissian M; Huynh L; Wang K; Wojciehowski J; Wu M; Wornson B; Niyazov A; Demetri GD Clin Cancer Res; 2022 Jan; 28(1):27-35. PubMed ID: 34667027 [TBL] [Abstract][Full Text] [Related]
6. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions. Wu J; Wang C; Toh S; Pisa FE; Bauer L Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065 [TBL] [Abstract][Full Text] [Related]
7. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information. Lau C; Jamali F; Loebenberg R J Pharm Pharm Sci; 2022; 25():227-236. PubMed ID: 35760071 [TBL] [Abstract][Full Text] [Related]
8. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics. Klonoff DC J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182 [TBL] [Abstract][Full Text] [Related]
9. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned. Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264 [TBL] [Abstract][Full Text] [Related]
10. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan. Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701 [TBL] [Abstract][Full Text] [Related]
11. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs. Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780 [TBL] [Abstract][Full Text] [Related]
12. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009. Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021 [TBL] [Abstract][Full Text] [Related]
13. Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness. Mahendraratnam N; Mercon K; Gill M; Benzing L; McClellan MB Clin Pharmacol Ther; 2022 Jan; 111(1):150-154. PubMed ID: 33891318 [TBL] [Abstract][Full Text] [Related]
14. Trial designs using real-world data: The changing landscape of the regulatory approval process. Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482 [TBL] [Abstract][Full Text] [Related]
15. The use of real-world evidence to support FDA post-approval study requirements for oncology drugs. Zettler ME Expert Rev Anticancer Ther; 2022 Jun; 22(6):657-666. PubMed ID: 35512688 [TBL] [Abstract][Full Text] [Related]
16. The use of real-world data/evidence in regulatory submissions. Song F; Zang C; Ma X; Hu S; Sun Q; Chow SC; Sun H Contemp Clin Trials; 2021 Oct; 109():106521. PubMed ID: 34339865 [TBL] [Abstract][Full Text] [Related]
17. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea. Lee H; Ahn HS; Kwon S; Kang HY; Han E Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484 [TBL] [Abstract][Full Text] [Related]
18. Real-world Data and Evidence to support a switch in status from Prescription drug to Over the Counter drug as applied by the EMA, the US FDA, the MHRA, and the BfArM. Kühler TC; Ateka A; Lassoued Z; Routhier FX; Mékary-Sawaya S Clin Ther; 2024 Mar; 46(3):208-216. PubMed ID: 38278703 [TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective. Zhu R; Vora B; Menon S; Younis I; Dwivedi G; Meng Z; Datta-Mannan A; Manchandani P; Nayak S; Tammara BK; Garhyan P; Iqbal S; Dagenais S; Chanu P; Mukherjee A; Ghobadi C; Clin Pharmacol Ther; 2023 Oct; 114(4):751-767. PubMed ID: 37393555 [TBL] [Abstract][Full Text] [Related]
20. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. DiMasi JA Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]